September 11, 2017 / 8:31 PM / 12 days ago

BRIEF-Teva announces sale of intrauterine contraceptive Paragard® to CooperSurgical

Sept 12 (Reuters) - Teva Pharmaceutical Industries Ltd

* Teva announces sale of Paragard® (intrauterine copper contraceptive) to CooperSurgical

* Teva Pharmaceutical Industries Ltd - deal for ‍$1.1 billion cash transaction.​

* Teva Pharmaceutical Industries Ltd - transaction includes Teva’s manufacturing facility in Buffalo, NY, which produces Paragard® exclusively​

* Teva - ‍continues to actively pursue additional divestiture opportunities, including sale of remaining assets of its global women’s health business​

* Teva Pharmaceutical Industries Ltd - ‍continues to actively pursue sale of its oncology and pain businesses in Europe​

* Teva Pharmaceutical Industries Ltd - ‍until transaction is completed, Teva will continue to manufacture and sell Paragard® in U.S. in normal course​

* Teva Pharmaceutical Industries Ltd - continues to expect to generate at least $2 billion in total proceeds from sale of these businesses

* Teva Pharmaceutical Industries Ltd - continues to expect additional asset sales to be executed by year end 2017 Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below